istvan4 : MIV Therapeutics!! aktuell 0,47 $ kursziel 1,53$!!
TUESDAY, APRIL 26, 2005 8:30 AM
NEW YORK, Apr 26, 2005 (BUSINESS WIRE) -- (Investrend Research Syndicate) MIV Technologies, Inc. (MIVT) has been rated "Outperform," with a price target of $1.53 by Investrend Research affiliate Beacon Equity Research. The report is authored by Senior Research Analyst, Shailesh Dhuri.
The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com
In the report Mr. Dhuri writes, "MIV is focusing on developing biocompatible device coatings, therapeutic stent technologies and drug delivery systems for drug-eluting applications... The Company holds worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is naturally found in the body as a main constituent of bone.
Currently, the Company claims to be the only firm which is undergoing trials with a fully biocompatible hydroxyapatite-based coating for stents. Tests conducted so far indicate a high probability that human bodies will accept MIV's HAp-coated stents without rejection, clotting or inflammation - the usual problems with stents.